JP2022540921A5 - - Google Patents

Info

Publication number
JP2022540921A5
JP2022540921A5 JP2022502559A JP2022502559A JP2022540921A5 JP 2022540921 A5 JP2022540921 A5 JP 2022540921A5 JP 2022502559 A JP2022502559 A JP 2022502559A JP 2022502559 A JP2022502559 A JP 2022502559A JP 2022540921 A5 JP2022540921 A5 JP 2022540921A5
Authority
JP
Japan
Prior art keywords
cancer
subject
compound
treating
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540921A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042162 external-priority patent/WO2021011674A1/en
Publication of JP2022540921A publication Critical patent/JP2022540921A/ja
Publication of JP2022540921A5 publication Critical patent/JP2022540921A5/ja
Pending legal-status Critical Current

Links

JP2022502559A 2019-07-15 2020-07-15 Krasまたはhras変異若しくは増幅を有するがんを処置する際に有用な方法 Pending JP2022540921A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874474P 2019-07-15 2019-07-15
US62/874,474 2019-07-15
PCT/US2020/042162 WO2021011674A1 (en) 2019-07-15 2020-07-15 Methods useful in treating cancers harboring a kras or hras mutation or amplification

Publications (2)

Publication Number Publication Date
JP2022540921A JP2022540921A (ja) 2022-09-20
JP2022540921A5 true JP2022540921A5 (cg-RX-API-DMAC7.html) 2023-07-26

Family

ID=74211326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502559A Pending JP2022540921A (ja) 2019-07-15 2020-07-15 Krasまたはhras変異若しくは増幅を有するがんを処置する際に有用な方法

Country Status (7)

Country Link
US (1) US20220257599A1 (cg-RX-API-DMAC7.html)
EP (1) EP3999049A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022540921A (cg-RX-API-DMAC7.html)
CN (1) CN114364377A (cg-RX-API-DMAC7.html)
AU (1) AU2020315388A1 (cg-RX-API-DMAC7.html)
CA (1) CA3147588A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021011674A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102679204B1 (ko) * 2021-02-10 2024-06-27 한국생명공학연구원 GPX4 저해제 및 Lp-PLA2 저해제를 포함하는 암 예방 또는 치료용 조성물
WO2024077085A1 (en) * 2022-10-07 2024-04-11 Memorial Sloan-Kettering Cancer Center Targeting phospholipase a2 (pla2) in cancer
US12314787B2 (en) 2023-04-27 2025-05-27 Hewlett Packard Enterprise Development Lp Serving application programming interface calls directed to hierarchical data format files stored in fabric-attached memories

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017671A1 (en) * 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
AU2012240154A1 (en) * 2011-04-06 2013-10-17 The Scripps Research Institute N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
CN102166364A (zh) * 2011-04-14 2011-08-31 江南大学 用于治疗卵巢癌的钙离子非依赖性磷脂酶a2的抑制剂
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors

Similar Documents

Publication Publication Date Title
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
Kalokasidis et al. The effect of Q‐switched Nd: YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo
Parashar et al. S‐adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications
Zhang et al. Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
JP2007530543A5 (cg-RX-API-DMAC7.html)
Liu et al. Does chlorhexidine improve outcomes in non-surgical management of peri-implant mucositis or peri-implantitis?: a systematic review and meta-analysis
Li et al. Epithelial–mesenchymal transition in pulmonary fibrosis: molecular mechanisms and emerging therapeutic strategies
Jebran et al. Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul
Pershing et al. Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer
Sápi et al. Linear state-feedback control synthesis of tumor growth control in antiangiogenic therapy
CN108079303A (zh) 鞘氨醇激酶抑制剂在制备治疗肝纤维化药物中的应用
WO2022266302A8 (en) Systems and methods for improved targeted therapy
Bijlsma et al. Are glucocorticoids DMARDs?
Salari-Sharif et al. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review
Zhu et al. Theogallin protects myocardial ischemia-reperfusion injury by inhibiting the interleukin-17 signaling pathway
Piretto et al. How combination therapies shape drug resistance in heterogeneous tumoral populations
Pastor et al. In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella
Bokotas et al. Wells syndrome: response to dapsone therapy
CN109512822A (zh) 一种治疗肝癌的联合药物组合物
Kotalik Multiple daily fractions in radiotherapy
Cheng et al. Dose rectification of an imbalance between DPP 4 and GLP‐1 ameliorates chronic stress‐related vascular aging and atherosclerosis?
CN109045013A (zh) Nifuroxazide的医药新用途
CN116920098B (zh) Depdc1在治疗肝癌中的应用
Soriano et al. Treatment of cutaneous larva migrans with a single session of carbon dioxide laser: a study of ten cases in the Philippines